protein

Recombinant Tafazzin (TAZ)

MBS2011264

0.01 mg

235 USD

Recombinant Protein

Recombinant Tafazzin (TAZ)

Tafazzin (TAZ)

tafazzin; Protein Taz; tafazzin; Barth syndrome); endocardial fibroelastosis 2; tafazzin (cardiomyopathy, dilated 3A (X-linked); tafazzin (cardiomyopathy, dilated 3A (X-linked); endocardial fibroelastosis 2; Barth syndrome); tafazzin

TAZ

Taz; Taz; Taz_mapped

Q4KLG6_RAT

E Coli

262

>98%

Supplied as lyophilized form in PBS,pH7.4, containing 5% sucrose, 0.01% sarcosyl.

Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months. Stability Test: The thermal stability is described by the loss rate of the targetprotein. The loss rate was determined by accelerated thermal degradation test,that is, incubate the protein at 37 degree C for 48h, and no obvious degradation andprecipitation were observed. (Referring from China Biological Products Standard,which was calculated by the Arrhenius equation.) The loss of this protein is lessthan 5% within the expiration date under appropriate storage condition.

Applications: SDS-PAGE; WB; ELISA; IP; CoIP; Purification; Amine Reactive Labeling. (May be suitable for use in other assays to be determined by the end user.)

Source: Prokaryotic expression. Residues: Asn46~Phe239. Tags: N-terminal His-Tag. Traits: Freeze-dried powder

Predicted isoelectric point: 9.0. Predicted Molecular Mass: 26.1kDa. Accurate Molecular Mass: 27kDa as determined by SDS-PAGE reducing conditions. Buffer formulation: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% sarcosyl, 5%Trehalose and Proclin300. Usage: Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

71043828

NP_001020919.1

NM_001025748.1

Q4KLG6

Acyl Chain Remodeling Of CL Pathway (935550); Glycerophospholipid Biosynthesis Pathway (935533); Glycerophospholipid Metabolism Pathway (83381); Glycerophospholipid Metabolism Pathway (364); Metabolism Pathway (935443); Metabolism Of Lipids And Lipoproteins Pathway (935480); Phospholipid Metabolism Pathway (935532)

human homolog may play a role in cardiolipin metabolism [RGD, Feb 2006]

tafazzin: Some isoforms may be involved in cardiolipin (CL) metabolism. Defects in TAZ are the cause of Barth syndrome (BTHS). An X-linked disease characterized by dilated cardiomyopathy with endocardial fibroelastosis, a predominantly proximal skeletal myopathy, growth retardation, neutropenia, and organic aciduria, particularly excess of 3-methylglutaconic acid. Additional features include hypertrophic cardiomyopathy, isolated left ventricular non-compaction, ventricular arrhythmia, motor delay, poor appetite, fatigue and exercise intolerance, hypoglycemia, lactic acidosis, hyperammonemia, and dramatic late catch-up growth after growth delay throughout childhood. Belongs to the taffazin family. 9 isoforms of the human protein are produced by alternative splicing. Protein type: Mitochondrial; Transferase; Membrane protein, integral. Cellular Component: membrane; mitochondrion; mitochondrial membrane; intrinsic to membrane; cytosol; nucleus. Molecular Function: 1-acylglycerophosphocholine O-acyltransferase activity; O-acyltransferase activity. Biological Process: inner mitochondrial membrane organization and biogenesis; cardiolipin biosynthetic process; cardiac muscle development; mitochondrial respiratory chain complex I assembly; skeletal muscle development; muscle contraction; cristae formation; heart development; hemopoiesis; organelle ATP synthesis coupled electron transport; cardiac muscle contraction

0.01 mg

235 USD

0.05 mg

535

0.1 mg

835